Abstract
MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Current Pharmaceutical Design
Title:Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies
Volume: 23 Issue: 39
Author(s): Xiaohong Du, Jitai Zhang, Juping Wang*, Xiaoming Lin*Feng Ding*
Affiliation:
- Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Collaborative and Creative Center of Molecular Pathology and Personalized Medicine, Department of Pathology, Shantou University Medical College, Shantou, Guangdong 515041,China
- Department of Thoracic Surgery, The first Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000,China
- Department of Physiology, School of Basic Medical Sciences, Wenzhou Medical University, Chashan Campus, Wenzhou, Zhejiang 325035,China
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Abstract: MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Export Options
About this article
Cite this article as:
Du Xiaohong , Zhang Jitai , Wang Juping *, Lin Xiaoming *, Ding Feng *, Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170714150118
DOI https://dx.doi.org/10.2174/1381612823666170714150118 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases
Current Drug Delivery Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry Novel Strategies and Model Studies for Colon Targeted Drug Delivery
Drug Delivery Letters Patented Biotechnological Applications of Serpin: an Update
Recent Patents on DNA & Gene Sequences Pretargeted Radioimmunotherapy with α-Particle Emitting Radionuclides
Current Radiopharmaceuticals Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer
Current Drug Targets Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Anatomical, Biochemical and Physiological Considerations of the Colon in Design and Development of Novel Drug Delivery Systems
Current Drug Delivery Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry